Charles River Announces Expansion of In Vitro Oncology Services
October 26 2017 - 8:00AM
Business Wire
Partnership with InSphero provides additional
3D solutions
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced its partnership with InSphero AG, a leading supplier of
3D solutions for in vitro drug discovery and development.
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20171026005121/en/
Through this partnership, Charles River will license its
collection of patient-derived xenograft (PDX) tumors to InSphero.
Additionally, Charles River will leverage InSphero’s proprietary 3D
cell culture technology to further extend and complement its
pre-clinical services, using in vitro 3D InSight™ Tumor
Microtissues derived from its existing PDX collection.
“Over the past year, we have seen an increased demand from our
oncology clients for enhanced speed and efficiency in early drug
discovery,” said Birgit Girshick, Corporate Senior Vice President,
Global Discovery Services at Charles River. “In vitro discovery
platforms offer a strong solution, and our partnership with
InSphero significantly bolsters our capabilities in this
field.”
In vitro 3D solutions enable the evaluation of a compound’s
potency compared to standard-of-care drugs. This in vitro testing
provides for identification of the most promising drug candidates,
tumor histotypes and molecular subtypes. Data collected in these
tests can then be used to select PDX models for subsequent in vivo
efficacy tests. The data can also be used to run systematic
combination therapy studies over a range of concentrations and to
correlate the tumor response with molecular data.
“Licensing Charles River’s robust library of PDX tumor models
significantly expands our current disease model portfolio in
diabetes and liver fibrosis,” said Jan Lichtenberg, Ph.D., Chief
Executive Officer and Co-Founder at InSphero. “The combination of
their extensive background in PDX tumors, combined with our
proprietary and industry-validated 3D cell culture technology, will
help pave the way for future breakthroughs. Expanding our 3D
InSight™ Discovery Platform to Charles River’s PDX models will
offer scalability, speed and unmet biological relevance in
vitro.”
Highlighting Scientific ExcellenceAt this week’s
AACR-NCI-EORTC International Conference on Molecular Targets and
Cancer Therapeutics: Discovery, Biology, and Clinical Applications,
the premier international meeting featuring novel cancer
therapeutics, Charles River is presenting two posters showcasing
its PDX research, including:
- Establishment and Characterization
of a Melanoma Patient-Derived Xenograft Model Comprising Three
Different Sublines with Distinct Biological Features
(Presented: Saturday, October 28, 12:30 p.m. to 4:00 p.m. EST)
- Targeting the WNT-Pathway in
3D-Cultured In Vitro PDX Models for Pancreas Cancer (Presented:
Saturday, October 28, 12:30 p.m. to 4:00 p.m. EST)
Reprints of each poster are available at Charles River’s booth
(#207) during the conference and oncology experts are available for
meetings with those interested in discussing research and drug
discovery.
To learn more about Charles River’s oncology research
capabilities, visit www.criver.com.
About InSpheroInSphero is the partner of choice for
leading pharmaceutical and biotechnology companies to bring safer,
more effective drugs to market faster through its robust and highly
physiologically relevant suite of 3D InSight™ Microtissues and
Services. InSphero patent-pending technologies and methods enable
large-scale, reproducible production of scaffold-free 3D
microtissues driven solely by cellular self-assembly. InSphero 3D
InSight™ Discovery Platforms include assay-ready and custom 3D
disease models derived from primary human liver, pancreas, and
tumor tissues that provide unrivalled biological insight into liver
fibrosis, diabetes, and cancer. InSphero microtissues are
thoroughly validated to ensure the highest quality, certified for
use in a variety of assays, and shipped globally to customers in a
patented, easy-to-use spheroid-optimized format, or accessible
through contract research services. For more information visit
www.insphero.com.
About Charles RiverCharles River provides essential
products and services to help pharmaceutical and biotechnology
companies, government agencies and leading academic institutions
around the globe accelerate their research and drug development
efforts. Our dedicated employees are focused on providing clients
with exactly what they need to improve and expedite the discovery,
early-stage development and safe manufacture of new therapies for
the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171026005121/en/
Charles River Laboratories International, Inc.Investor
Contact:Susan E. Hardy, 781-222-6190Corporate Vice President,
Investor Relationssusan.hardy@crl.comorMedia Contact:Amy
Cianciaruso, 781-222-6168Corporate Vice President, Public
Relationsamy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Apr 2023 to Apr 2024